Genetic testing for breast cancer risk is recommended for a defined group, not everyone: per the US Preventive Services Task Force's 2019 recommendation, women whose personal or family history suggests inherited risk — breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with BRCA mutations, such as Ashkenazi Jewish ancestry — should be offered genetic counseling first and, if the counselor finds indication, testing. For women without such history, the Task Force found insufficient evidence to support routine risk assessment or testing, because the odds of a meaningful finding are low and false reassurance and anxiety are real.
The genes at the center of this are BRCA1 and BRCA2, which normally repair DNA damage; when a harmful mutation is inherited, lifetime breast cancer risk rises steeply — a landmark study in JAMA (Kuchenbaecker et al., 2017) estimated breast cancer risk by age 80 of about 72 percent for BRCA1 carriers and 69 percent for BRCA2 carriers, compared with roughly 13 percent for women overall per the National Cancer Institute. This article explains who the guidelines suggest testing, what the process involves, and what a result does and does not mean. It publishes information, not medical advice — testing decisions belong with you, a genetic counselor, and your clinician.
How common are BRCA mutations?
Rare in the general population, common in certain families. Per CDC estimates, about 1 in 500 women in the US carries a BRCA1 or BRCA2 mutation — but among women of Ashkenazi Jewish ancestry, the figure is about 1 in 40, which is why ancestry alone is a guideline trigger for risk assessment. Hereditary mutations overall account for an estimated 5 to 10 percent of breast cancers, per the National Cancer Institute, with BRCA1/2 the most common contributors, followed by genes such as PALB2, CHEK2, and ATM that current multi-gene panels also detect. Family patterns that raise suspicion include breast cancer before 50, cancer in both breasts, ovarian cancer at any age, male breast cancer in the family, and combinations of breast, pancreatic, and prostate cancers.
What do the major guidelines actually recommend?
The USPSTF's 2019 statement, still the primary-care reference, describes a two-step pathway: first, use family history tools to identify women who might carry a BRCA-related mutation; second, refer them for genetic counseling, and offer testing only if the counselor concludes it is indicated. NCCN's genetics guidelines, updated regularly through this period, define detailed testing criteria for clinicians — they include ovarian cancer at any age, breast cancer diagnosed at or under 45, male breast cancer, pancreatic cancer, and specific family-history combinations, with lower thresholds for Ashkenazi ancestry. The consistent principle across bodies: testing is targeted, not universal, and it is preceded by counseling.
Why is genetic counseling mandatory before testing?
Because the test is small and the consequences are not. A genetic counselor reviews your family tree, estimates the chance of finding a mutation, explains which genes a panel covers, and prepares you for every category of result before any blood or saliva is drawn — including the results people are least prepared for. Counseling also covers insurance protections and the reality that a positive result has implications for siblings, children, and parents, who may then choose cascade testing — the practice of testing relatives for the specific family mutation once it is known, which per CDC analysis is how most carriers in a family are actually found.
What do the possible results mean?
Three categories, and only one is clear-cut. A pathogenic variant is a confirmed harmful mutation — actionable, with defined options described below. A negative result means no mutation was found; in a family with a known mutation, this is genuinely reassuring, but in a family without one it does not mean hereditary risk is absent — the family pattern may be caused by a gene not on the panel or not yet discovered. The third category is the variant of uncertain significance (VUS): a gene change whose effect science has not established. Per genetics-society guidance, a VUS should not be treated as either positive or negative, and most are reclassified over time as evidence accumulates — which is why a VUS result comes with a recommendation to recontact the testing lab periodically rather than to act.
Related stories: STI Screening: What the Guidelines Actually Recommend for Women, and When · Osteoporosis Screening: When a DXA Scan Makes Sense, and What the Result Means.
What happens after a positive result?
A positive BRCA result opens a menu, and nothing on it is obligatory. Per the American Cancer Society's 2015 screening guideline and NCCN guidance, carriers are typically offered intensified surveillance — annual breast MRI alongside mammography beginning around age 25 — which finds cancers earlier in dense, high-risk breasts. Risk-reducing options enter the conversation on their own timeline: risk-reducing mastectomy, which studies following BRCA carriers have shown substantially lowers breast cancer risk, and removal of the ovaries and fallopian tubes, which per prospective research published in JAMA (Finch et al., 2014) reduces ovarian and related cancers in BRCA1/2 carriers and is timed to age and family plans. Medication risk reduction also exists for some carriers. These are major, personal decisions made with a care team — the guidelines define the options, not the answers.
What about direct-to-consumer tests?
Handle them as partial tools. The FDA authorized a consumer test for three specific BRCA variants in 2018, but those three are found mainly in people of Ashkenazi ancestry, and they are only three of thousands of known BRCA mutations. Per the FDA's own announcement, a negative result on that test does not rule out a BRCA mutation or hereditary cancer risk — most carriers would test negative and remain at unassessed risk. A concerning family history warrants a comprehensive clinical panel ordered through a clinician or counselor, which covers far more genes and comes with professional interpretation attached.
Are there legal protections around testing?
There are, with edges. The Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits health insurers and employers from using genetic test results to discriminate — denying coverage or employment decisions based on genetic risk. GINA does not cover life insurance, disability insurance, or long-term care insurance, and it does not apply to employers under 15 employees; counselors discuss this gap as part of pre-test education, since it is a genuine factor some women weigh before testing.
When to talk to a clinician
Raise the topic at your next visit if you have breast cancer diagnosed at or before age 45 anywhere in your family; a relative with ovarian, male breast, or pancreatic cancer; two or more relatives with breast or related cancers on one side of the family; Ashkenazi Jewish ancestry combined with any breast or ovarian cancer in the family; or your own breast cancer diagnosis — in which case testing discussion is standard of care and can shape surgical and treatment decisions. And if you tested years ago with an older, single-gene test or received a VUS result, that is itself a reason to revisit: panels have expanded and classifications have moved.
Frequently asked questions
Does a negative BRCA test mean I can skip screening?
No. Per the USPSTF's framework, routine screening recommendations — mammography per your age — apply regardless of test result, and a negative test in a family without a known mutation does not eliminate risk, hereditary or otherwise. What a negative result changes is the intensity of surveillance: without a mutation and without an elevated family-risk estimate, you return to age-based guidelines rather than MRI-based high-risk protocols.
My mother had breast cancer at 60. Do I qualify for testing?
Quite possibly not on its own — late-onset single-relative histories usually fall below NCCN testing criteria, which is the point of counseling: a professional weighs your whole family structure, ages, and related cancers. Some women qualify; many get a documented risk assessment, an early conversation about screening, and a clear threshold for when to return. Either outcome is useful, and the referral costs nothing but a visit.
If I carry a BRCA mutation, will I definitely get breast cancer?
No — penetrance is high but not complete. The JAMA 2017 estimates place lifetime breast cancer risk near 72 percent for BRCA1 and 69 percent for BRCA2 carriers by age 80, meaning roughly three in ten carriers never develop it, and risk varies by family and specific mutation. The number is the reason guidelines offer aggressive surveillance and risk-reducing options — and the incompleteness is why those options remain choices, not mandates.
Can men carry and pass on BRCA mutations?
Yes — BRCA mutations are inherited from either parent, and men who carry them face elevated risks of breast (though far lower than women's), prostate, and pancreatic cancers, per NCI summaries. A father can transmit the mutation just as a mother can, which is why counselors build the family tree on both sides — and why male relatives' cancers count as much as female ones when criteria are assessed.